Exanthem disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

RASH MCID: EXN002 MIFTS: 56	Exanthem (RASH) Categories: Infectious diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Exanthem

MalaCards integrated aliases for Exanthem:

Name: Exanthem ¹² ¹⁵

Exanthema ¹² ⁴⁴

Rash ¹² ¹⁵

Rashes ⁴³

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Symptoms and signs involving the skin and subcutaneous tissue

Rash and other nonspecific skin eruption

External Ids:

Disease Ontology ¹² DOID:0050486

ICD10 ³³ R21

ICD9CM ³⁵ 782.1

MeSH ⁴⁴ D005076

NCIt ⁵⁰ C111884 C39594

SNOMED-CT ⁶⁸ 1806006

UMLS ⁷³ C0015230

Sources

Summaries for Exanthem

MedlinePlus : ⁴³ A rash is an area of irritated or swollen skin. Many rashes are itchy, red, painful, and irritated. Some rashes can also lead to blisters or patches of raw skin. Rashes are a symptom of many different medical problems. Other causes include irritating substances and allergies. Certain genes can make people more likely to get rashes. Contact dermatitis is a common type of rash. It causes redness, itching, and sometimes small bumps. You get the rash where you have touched an irritant, such as a chemical, or something you are allergic to, like poison ivy. Some rashes develop right away. Others form over several days. Although most rashes clear up fairly quickly, others are long-lasting and need long-term treatment. Because rashes can be caused by many different things, it's important to figure out what kind you have before you treat it. If it is a bad rash, if it does not go away, or if you have other symptoms, you should see your health care provider. Treatments may include moisturizers, lotions, baths, cortisone creams that relieve swelling, and antihistamines, which relieve itching.

MalaCards based summary : Exanthem, also known as exanthema, is related to drug reaction with eosinophilia and systemic symptoms and aseptic meningitis. An important gene associated with Exanthem is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Irinotecan and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and breast, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : ¹² A skin disease that is characterized by a rash that results from a variety of causes including bacteria, viruses, toxins, drugs and autoimmune disorders.

Wikipedia : ⁷⁶ An exanthem or exanthema (from Greek ἐξάνθημα exánth�?ma, "a breaking out") is a widespread rash usually... more...

Sources

Related Diseases for Exanthem

Diseases in the Exanthem family:

Bacterial Exanthem

Viral Exanthem

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 318)

#	Related Disease	Score	Top Affiliating Genes
1	drug reaction with eosinophilia and systemic symptoms	30.5	CRP TNF
2	aseptic meningitis	30.4	IL1RN NLRP3 TNF
3	meningitis	30.2	CRP IL6 NLRP3 TLR9 TNF
4	viral infectious disease	30.2	IL2 IL6 TLR9 TNF
5	mouth disease	30.1	CRP IL6 TLR9 TNF
6	arthritis	30.0	IL1RN IL6 TNF TNFRSF1B
7	pneumonia	30.0	CRP IL6 TLR9 TNF
8	kawasaki disease	29.9	CRP IL6 TNF
9	human immunodeficiency virus infectious disease	29.9	IL2 IL6 TLR9 TNF
10	lyme disease	29.9	CRP IL6 TNF
11	gastroenteritis	29.9	CRP IL6 TNF
12	purpura	29.9	CRP IL6 TNF
13	graft-versus-host disease	29.8	IL2 IL6 TNF
14	acquired immunodeficiency syndrome	29.8	IL2 IL6 TNF
15	exanthema subitum	29.8	IL2 IL6 TNFRSF1B
16	lung disease	29.8	EGFR IL6 TLR9 TNF
17	pericarditis	29.7	CRP IL1RN IL6 TNF
18	brucellosis	29.6	CRP IL1RN IL2 IL6 TNF
19	myeloma, multiple	29.3	CRP HRAS IL2 IL6 KRAS TLR9
20	leukemia, acute myeloid	29.3	HRAS IL2 KRAS MAP2K7 MTOR TNF
21	psoriasis	29.0	AREG IL2 IL6 TLR9 TNF TNFRSF1B
22	bacterial exanthem	12.3
23	viral exanthem	12.3
24	severe cutaneous adverse reaction	11.4
25	hand, foot and mouth disease	11.4
26	contagious pustular dermatitis	11.1
27	progesterone-receptor negative breast cancer	10.3	EGFR ERBB2
28	breast scirrhous carcinoma	10.3	EGFR ERBB2
29	apocrine adenoma	10.3	HRAS KRAS
30	systemic onset juvenile idiopathic arthritis	10.3	IL1RN TNF
31	measles	10.3
32	hyperglobulinemic purpura	10.3	HSPG2 TRIM21
33	skin sarcoidosis	10.3	TNF TNFRSF1B
34	cold agglutinin disease	10.3	CRP IL6
35	colorectal adenocarcinoma	10.3	EGFR HRAS KRAS
36	subacute cutaneous lupus erythematosus	10.3	TNF TRIM21
37	differentiated thyroid carcinoma	10.3	EGFR HRAS KRAS
38	breast intraductal proliferative lesion	10.3	EGFR ERBB2
39	uterine carcinosarcoma	10.3	EGFR ERBB2 HRAS
40	endometrial adenocarcinoma	10.3	EGFR ERBB2 KRAS
41	colorectal adenoma	10.3	CRP HRAS KRAS
42	schnitzler syndrome	10.2	CRP IL1RN NLRP3
43	systemic scleroderma	10.2	CRP TLR9 TRIM21
44	carcinosarcoma	10.2	ERBB2 HRAS KRAS
45	angioimmunoblastic lymphadenopathy with dysproteinemia	10.2	IL6 TNF
46	leukomalacia	10.2	IL6 TNF
47	scorpion envenomation	10.2	IL6 TNF
48	arthropathy	10.2	CRP NLRP3 TNF
49	renal cell carcinoma, papillary, 1	10.2	ERBB2 HRAS MTOR
50	vulvar vestibulitis syndrome	10.2	IL1RN NLRP3 TNF

Graphical network of the top 20 diseases related to Exanthem:

Sources

Symptoms & Phenotypes for Exanthem

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

²⁶ (show all 20)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-2	10.59	EGFR HRAS KRAS MTOR KALRN
2	Decreased viability	GR00106-A-0	10.59	KRAS
3	Decreased viability	GR00221-A-1	10.59	EGFR HRAS KRAS MAP2K7 MTOR
4	Decreased viability	GR00221-A-2	10.59	HRAS KRAS
5	Decreased viability	GR00221-A-3	10.59	HRAS
6	Decreased viability	GR00221-A-4	10.59	EGFR MTOR
7	Decreased viability	GR00301-A	10.59	KRAS KALRN
8	Decreased viability	GR00342-S-1	10.59	MAP2K7 MTOR KALRN
9	Decreased viability	GR00342-S-2	10.59	MTOR KALRN
10	Decreased viability	GR00342-S-3	10.59	KALRN
11	Decreased viability	GR00381-A-1	10.59	KRAS KALRN
12	Decreased viability	GR00402-S-2	10.59	EGFR HRAS KRAS MAP2K7 MTOR KALRN
13	Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance	GR00210-A	9.8	EGFR ERBB2 HRAS HSPG2 KALRN MTOR
14	Decreased cell migration	GR00055-A-1	9.77	EGFR HRAS KALRN KRAS MTOR
15	Decreased viability with paclitaxel	GR00179-A-1	9.7	EGFR MTOR ERBB2
16	Decreased viability with paclitaxel	GR00179-A-2	9.7	MTOR
17	Decreased viability with paclitaxel	GR00179-A-3	9.7	EGFR MTOR
18	Decreased substrate adherent cell growth	GR00193-A-2	9.65	EGFR KALRN MAP2K7 MTOR
19	Decreased substrate adherent cell growth	GR00193-A-3	9.65	MAP2K7
20	Reduced mammosphere formation	GR00396-S	9.17	EGFR HRAS HSPG2 KRAS MTOR TLR9

MGI Mouse Phenotypes related to Exanthem:

⁴⁶ (show all 23)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.53	AREG CRP CTLA4 EGFR ERBB2 HRAS
2	cardiovascular system	MP:0005385	10.48	AREG CRP CTLA4 EGFR ERBB2 HRAS
3	mortality/aging	MP:0010768	10.45	AREG CTLA4 EGFR ERBB2 HRAS HSPG2
4	hematopoietic system	MP:0005397	10.43	AREG CTLA4 EGFR HSPG2 IL1RN IL2
5	cellular	MP:0005384	10.41	EGFR ERBB2 HSPG2 IL1RN IL2 IL6
6	growth/size/body region	MP:0005378	10.41	AREG EGFR ERBB2 HRAS HSPG2 IL1RN
7	immune system	MP:0005387	10.41	AREG CRP CTLA4 EGFR HSPG2 IL1RN
8	digestive/alimentary	MP:0005381	10.4	AREG CTLA4 EGFR ERBB2 HRAS HSPG2
9	integument	MP:0010771	10.4	AREG CTLA4 EGFR ERBB2 HRAS HSPG2
10	endocrine/exocrine gland	MP:0005379	10.39	AREG CTLA4 EGFR ERBB2 HRAS IL2
11	behavior/neurological	MP:0005386	10.35	ERBB2 HRAS HSPG2 IL2 IL6 KALRN
12	nervous system	MP:0003631	10.21	EGFR ERBB2 HRAS HSPG2 IL6 KALRN
13	liver/biliary system	MP:0005370	10.16	CTLA4 EGFR HSPG2 IL2 IL6 KRAS
14	craniofacial	MP:0005382	10.14	EGFR ERBB2 HRAS HSPG2 KRAS TNF
15	muscle	MP:0005369	10.13	EGFR ERBB2 HSPG2 IL6 KALRN KRAS
16	neoplasm	MP:0002006	10.11	EGFR ERBB2 HRAS IL2 IL6 KRAS
17	normal	MP:0002873	10.07	CTLA4 EGFR ERBB2 HRAS KALRN KRAS
18	reproductive system	MP:0005389	10	AREG EGFR ERBB2 IL1RN IL2 IL6
19	renal/urinary system	MP:0005367	9.97	EGFR HRAS IL6 KRAS MTOR NLRP3
20	no phenotypic analysis	MP:0003012	9.95	EGFR HRAS IL2 KALRN KRAS MTOR
21	respiratory system	MP:0005388	9.9	CTLA4 EGFR ERBB2 HRAS HSPG2 IL2
22	skeleton	MP:0005390	9.73	CTLA4 EGFR ERBB2 HRAS HSPG2 IL1RN
23	vision/eye	MP:0005391	9.28	AREG EGFR HSPG2 IL2 IL6 KRAS

Sources

Drugs & Therapeutics for Exanthem

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1219)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Irinotecan

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

100286-90-6, 97682-44-5

60838

leucovorin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

58-05-9

6006 143

Phytonadione

Approved, Investigational

Phase 4,Phase 2,Phase 1,Not Applicable

84-80-0

4812 5284607

Cetuximab

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

205923-56-4

56842117 2333

Fluorouracil

Approved

Phase 4,Phase 3,Phase 2,Phase 1

51-21-8

3385

Zinc

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

7440-66-6

Zinc oxide

Approved

Phase 4,Phase 3,Not Applicable

1314-13-2

Vancomycin

Approved

Phase 4,Phase 3,Not Applicable

1404-90-6

14969 441141

Chlorhexidine

Approved, Vet_approved

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

55-56-1

2713 9552079

Mupirocin

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Not Applicable

12650-69-0

446596

Salicylic acid

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

69-72-7

338

gamma-Aminobutyric acid

Approved, Investigational

Phase 4,Phase 2

56-12-2

119

Gabapentin

Approved, Investigational

Phase 4,Phase 2

60142-96-3

3446

Piperacillin

Approved

Phase 4,Not Applicable

66258-76-2

43672

Sulbactam

Approved

Phase 4,Phase 2

68373-14-8

Pyrimethamine

Approved, Investigational, Vet_approved

Phase 4,Phase 1,Phase 2

58-14-0

4993

Azithromycin

Approved

Phase 4,Phase 3,Phase 2,Early Phase 1

83905-01-5

55185 447043

Sulfadoxine

Approved, Investigational

Phase 4,Phase 1,Phase 2

2447-57-6

17134

Ketorolac

Approved

Phase 4,Not Applicable

66635-83-4, 74103-06-3

3826

Latanoprost

Approved, Investigational

Phase 4

130209-82-4

5311221 5282380

Travoprost

Approved

Phase 4

157283-68-6

5282226

Iron

Approved

Phase 4,Phase 2,Phase 1,Not Applicable

7439-89-6

23925

Ferrous fumarate

Approved

Phase 4

141-01-5

Cefazolin

Approved

Phase 4,Phase 3,Not Applicable

25953-19-9

656510 33255

Histamine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

51-45-6, 75614-87-8

774

Ketotifen

Approved

Phase 4,Phase 3

34580-14-8, 34580-13-7

3827

Dapsone

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

80-08-0

2955

Benzoyl peroxide

Approved

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

94-36-0

7187

Clindamycin

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

18323-44-9

29029

Ranibizumab

Approved

Phase 4,Phase 3,Phase 1,Phase 2

347396-82-1

459903

Pinaverium

Approved

Phase 4

59995-65-2

Salmon Calcitonin

Approved, Investigational

Phase 4,Not Applicable

47931-85-1

16129616

Tazobactam

Approved

Phase 4

89786-04-9

123630

Penicillin G

Approved, Vet_approved

Phase 4

61-33-6

5904

Cefuroxime

Approved

Phase 4,Phase 2,Not Applicable

55268-75-2

5361202 5479529

Clarithromycin

Approved

Phase 4,Not Applicable

81103-11-9

84029

Ciprofloxacin

Approved, Investigational

Phase 4,Phase 2,Phase 1,Not Applicable

85721-33-1

2764

Moxifloxacin

Approved, Investigational

Phase 4,Phase 1

354812-41-2, 151096-09-2

152946

Tocopherol

Approved, Investigational

Phase 4,Not Applicable

1406-66-2

14986

Prednisone

Approved, Vet_approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

53-03-2

5865

Nevirapine

Approved

Phase 4,Phase 3,Phase 1,Phase 2

129618-40-2

4463

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

22916-47-8

4189

sodium fluoride

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

7681-49-4

Lamivudine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

134678-17-4

60825

Tacrolimus

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

104987-11-3

445643 439492

Sunitinib

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

557795-19-4, 341031-54-7

5329102

Caffeine

Approved

Phase 4,Phase 1,Not Applicable

58-08-2

2519

Morphine

Approved, Investigational

Phase 4,Phase 3,Not Applicable

57-27-2

5288826

Sorafenib

Approved, Investigational

Phase 4,Phase 2

284461-73-0

216239 406563

Nicotinamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

98-92-0

936

Interventional clinical trials:

(show top 50) (show all 3200)

#	Name	Status	NCT ID	Phase	Drugs
1	Elmex Gel Efficacy in Preventing White Spot Lesions	Unknown status	NCT00268138	Phase 4	elmex gel
2	FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema	Unknown status	NCT01315990	Phase 4	FOLFIRI + Cetuximab
3	Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants	Unknown status	NCT02716415	Phase 4	Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
4	Line Versus Spot Ablation in Persistent Atrial Fibrillation	Unknown status	NCT00196157	Phase 4
5	Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients	Unknown status	NCT02605213	Phase 4	Vancomycin;Placebo
6	Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease	Unknown status	NCT01753401	Phase 4	Acthar;Placebo for Acthar
7	Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection	Unknown status	NCT02547103	Phase 4
8	Effectiveness and Economic Evaluation of Glass Ionomer Material Using as Dental Sealant	Unknown status	NCT03034837	Phase 4	resin sealant;ART sealant
9	A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder	Unknown status	NCT00837343	Phase 4	quetiapine fumarate tablet (Seroquel)
10	Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission	Unknown status	NCT01901666	Phase 4	Growth Hormone
11	Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome	Unknown status	NCT02424695	Phase 4	Gabapentin Enacarbil (GEn);Placebo
12	Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old	Unknown status	NCT02806531	Phase 4
13	Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection	Unknown status	NCT01897831	Phase 4	xin te mie
14	Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection	Unknown status	NCT01760109	Phase 4	Piperacillin Sodium and Sulbactam Sodium
15	A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women	Unknown status	NCT02575755	Phase 4	Azithromycin plus piperaquine phosphate;Sulfadoxine-pyrimethamine
16	The Laser in Pseudoexfoliation (LIP) Study	Unknown status	NCT01704989	Phase 4	Prostagladin
17	Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension	Unknown status	NCT02796560	Phase 4	Brand name travoprost;Generic travoprost
18	The Use of Iron Therapy for Patients With Anemia After Surgery	Unknown status	NCT01975272	Phase 4	Ferinject;Ferrous fumarate;Placebo for ferrous fumarate;Placebo for ferinject
19	The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection	Unknown status	NCT02307006	Phase 4	Ceftaroline;Cefazolin / Vancomycin
20	Ketotifen as a Treatment for Vascular Leakage During Dengue Fever	Unknown status	NCT02673840	Phase 4	Ketotifen;Placebo
21	Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris	Unknown status	NCT02944461	Phase 4	Dapsone 7.5 % gel
22	Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris	Unknown status	NCT01448733	Phase 4	Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
23	A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne	Unknown status	NCT01422785	Phase 4	clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
24	Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples)	Unknown status	NCT01260571	Phase 4	Benzoyl peroxide and sulfur
25	Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study	Unknown status	NCT02834663	Phase 4	Lucentis
26	Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)	Unknown status	NCT01553032	Phase 4	Erbitux®
27	Targeted Indoor Residual Spraying Against Malaria	Unknown status	NCT02556242	Phase 4
28	Pinaverium Bromide in Post-cholecystectomy Sphincter of Oddi Dysfunction	Unknown status	NCT02833103	Phase 4	Danshu Capsules;Pinaverium Bromide
29	Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections	Unknown status	NCT02171338	Phase 4
30	Clinical Study to Evaluate the Efficacy and Safety of Two Marketed Investigational Products in Children With Diaper Rash	Completed	NCT00219466	Phase 4
31	Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT	Completed	NCT00647205	Phase 4
32	MI Varnish for the Prevention of White Spot Lesions	Completed	NCT03446690	Phase 4	MI Varnish
33	Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients	Completed	NCT01329731	Phase 4	elmex® gelée;negative control (placebo)
34	Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients	Completed	NCT02184299	Phase 4	Nevirapine;Prednisone
35	Lumefantrine in Venous Plasma Versus Dried Capillary Blood Spot	Completed	NCT02742285	Phase 4	Artemether + lumefantrine
36	Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study	Completed	NCT00723515	Phase 4	sodium fluoride;sodium fluoride calcium fluoride
37	MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study	Completed	NCT02424097	Phase 4	CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste;1,100pm F-toothpaste and 0.5%NaF rinse
38	Caries-preventive Effect of a Dentifrice Containing 5,000 Ppm Fluoride in Orthodontic Patients	Completed	NCT01768390	Phase 4
39	Genotype Based Personalized Prescription of Nevirapine	Completed	NCT00986063	Phase 4
40	Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction	Completed	NCT02131220	Phase 4	Prourokinase;Tirofiban;normal saline
41	Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots	Completed	NCT01149876	Phase 4	Tretinoin cream 0.05
42	Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants	Completed	NCT00702507	Phase 4	0.25 % Miconazole Nitrate Ointment
43	Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity.	Completed	NCT01195194	Phase 4	PRE-TRANSPLANT (PRE=before)
44	Comparison of the Effect of Fluoride Remineralizer Gel and Foam	Completed	NCT02490592	Phase 4
45	Efficacy of Pentoxifylline on Chronic Kidney Disease	Completed	NCT00155246	Phase 4	pentoxifylline (drug)
46	Subcutaneous Amifostine Safety Study	Completed	NCT00158041	Phase 4	Amifostine administered subcutaneously
47	Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy	Completed	NCT01797861	Phase 4
48	Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study in China	Completed	NCT02898922	Phase 4
49	SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle	Completed	NCT01242852	Phase 4
50	Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients	Completed	NCT01402089	Phase 4	Sunitinib;Erlotinib;Midazolam;Caffeine

Search NIH Clinical Center for Exanthem

Cochrane evidence based reviews: exanthema

Sources

Genetic Tests for Exanthem

Sources

Anatomical Context for Exanthem

MalaCards organs/tissues related to Exanthem:

⁴¹

Skin, Testes, Breast, Myeloid, Prostate, Lung, Kidney

Sources

Publications for Exanthem

Articles related to Exanthem:

(show top 50) (show all 494)

#	Title	Authors	Year
1	Ten-year-old traveller with fever and an exceptional exanthem. ( 29314384 )		2018
2	Acral-accentuated exanthem in an infant with parechovirus meningitis. ( 29205494 )	Lee D....Chong J.	2018
3	What's in a Rash? Viral Exanthem Versus CBRNE Exposure: Teleconsultation Support for Two Special Forces Soldiers With Diffuse Rash in an Austere Environment. ( 29889970 )	Lee H.D....Pamplin J.C.	2018
4	Asymmetric periflexural exanthem: not a distinctive disease of childhood. ( 29582621 )	Balestri R....Girardelli C.R.	2018
5	Ten-year-old traveller with fever and an exceptional exanthem. ( 29314380 )		2018
6	50 Years Ago in The Journal of Pediatrics: Atypical Exanthem after Exposure to Natural Measles: Eleven Cases in Children Previously Inoculated with Killed Vaccine. ( 29389454 )		2018
7	Exanthem, Fieber und Arthralgien bei einer 19-jAohrigen Patientin. ( 29645383 )		2018
8	Eosinophilia, pruritic exanthema and digital necrosis. ( 28624075 )	Gallo-Padilla L...Ortego-Centeno N	2018
9	Infant with exanthema and fever. ( 27876188 )	Barbed-Ferr?ndez S...Bustillo-Alonso M	2018
10	Immunohistochemical Demonstration of Parvovirus B19 Viral Protein 2 in Periflexural Exanthema in an Adult, Supporting Antibody-Dependent Enhancement as Means of Endothelial Uptake of the Virus. ( 28700372 )	Santonja C...Requena L	2018
11	Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. ( 29288229 )	McCormack M...Cavalleri GL	2018
12	A 62-Year-Old Woman With Fever and Exanthema. ( 29521699 )	Mart?n-Iglesias D...Barrios-Blandino A	2018
13	Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients. ( 29546073 )	Sukasem C...Aekplakorn W	2018
14	Overlap Between DRESS Syndrome and Exanthema Induced by Sulfadiazine in a Patient Treated With Sulfamethoxazole: Utility of the Lymphocyte Transformation Test for Identification of the Culprit Drug. ( 29661742 )	Monge-Ortega OP...Bell?n T	2018
15	Tacrolimus-induced symmetric drug-related intertriginous and flexural exanthema (SDRIFE). ( 29722025 )	Scherrer M...Farah K	2018
16	Clindamycin-induced Maculopapular Exanthema with Preferential Involvement of Striae Distensae: A Koebner phenomenon? ( 29782303 )	Monteagudo B...Su?rez-Amor ?	2018
17	First case of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) due to Berberine, an over-the-counter herbal glycemic control agent. ( 29808929 )	Labadie JG...Krunic AL	2018
18	Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) associated with pristinamycin, secnidazole, and nefopam, with a review of the literature. ( 30062790 )	Nespoulous L...Assikar S	2018
19	Palmoplantar exanthema and liver dysfunction. ( 30102597 )	Fujikawa T...Matsuura H	2018
20	Diffuse maculopapular exanthema and a positive lymphocyte transformation test reaction in response to clarithromycin. ( 30159155 )	Ito T	2018
21	Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. ( 30323078 )		2018
22	Unilateral laterothoracic exanthem. ( 28754336 )	Lozano-Masdemont B.	2017
23	Can Unilateral Pityriasis Rosea be Considered a Form of Superimposed Lateralized Exanthem? ( 28764276 )	Drago F....Parodi A.	2017
24	TherapierefraktAores Exanthem eines sechs Monate alten SAouglings. ( 29228485 )	Weingast J....Radakovic S.	2017
25	Superimposed lateralized exanthem in a 30-year-old woman. ( 28893877 )	AlcA!ntara-Reifs C.M....Salido-Vallejo R.	2017
26	Image Gallery: Flagellate bullous exanthem in chikungunya. ( 29052889 )	Vinay K....Dogra S.	2017
27	Epstein-Barr virus exanthem in an adult patient with myelodysplastic syndrome. ( 29274098 )	Drago F....Rebora A.	2017
28	Exanthem und Ekzem bei einem anderthalbjAohrigen Jungen. ( 28214315 )		2017
29	Dengue-Fieber und die Differenzialdiagnosen zu Exanthem, Fieber und Kopfschmerzen nach Fernreise. ( 28140551 )		2017
30	IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem. ( 28856664 )		2017
31	Assessment of histopathological features of maculopapular viral exanthem and drug-induced exanthem. ( 28914958 )		2017
32	Acute localized exanthem due to Coxsackievirus A4. ( 28956547 )		2017
33	Drug-specific CD4+ T-cell immune responses are responsible for antituberculosis drug-induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome. ( 27373553 )	Ye YM...Kim SH	2017
34	Exanthema, fever and arthralgia in a pregnant woman. ( 26493355 )	Puente-Pablo N...Borbujo J	2017
35	Fixed exanthema emerged following narrowband ultraviolet B irradiation. ( 27543011 )	Honma M...Ishida-Yamamoto A	2017
36	Occurrence of equine coital exanthema (ECE) in stallions in Japan and effectiveness of treatment with valacyclovir for ECE. ( 28123140 )	Toishi Y...Kirisawa R	2017
37	Isolation of equine herpesvirus 3 (EHV-3) from equine coital exanthema of two stallions and sero-epidemiology of EHV-3 infection in Japan. ( 28132964 )	Kirisawa R...Tsunoda N	2017
38	Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by golimumab. ( 28217835 )	Yang SY...Hu SC	2017
39	Symmetrical drug-related intertriginous and flexural exanthema possibly due to thiamine disulfide. ( 28225167 )	Hattori Y...Seishima M	2017
40	Main Characteristics of Zika Virus Exanthema in Guadeloupe. ( 28241170 )	Cordel N...Herrmann Storck C	2017
41	Pustulobullous variant of SDRIFE (symmetrical drug-related intertriginous and flexural exanthema). ( 28514083 )	Magnolo N...St?nder S	2017
42	Pustulobullöse Variante eines SDRIFE (symmetrical drug-related intertriginous and flexural exanthema). ( 28591434 )	Magnolo N...St?nder S	2017
43	Cutaneous Drug REactions: Annular, polycyclic erythematous exanthema in an oncology patient. ( 28677584 )	Hernandez-Aragues I...Vilas-Boas PT	2017
44	Allergic Maculo-Papular Exanthema Due To Terbinafine. ( 28785353 )	Koch A...Wollina U	2017
45	Symmetrical drug-related intertriginous and flexural exanthema induced by clarithromycin. ( 28954125 )	Moreira C...Azevedo F	2017
46	Symmetric Drug-related Intertriginous and Flexural Exanthema due to Itraconazole: An Uncommon Side Effect of a Commonly Used Drug. ( 29204404 )	Mohapatra M...Raj C	2017
47	Symmetrical Drug-related Intertriginous and Flexural Exanthema Induced by Doxycycline. ( 29340257 )	Li DG...Mostaghimi A	2017
48	Asymmetric periflexural/unilateral laterothoracic exanthem related to parvovirus B19 infection: An adult carrier of A9-globin thalassaemia gene mutation in Hong Kong. ( 29896828 )	Chuh A.	2016
49	Eruptive Hypomelanosis in a Young Child as a &quot;Paraviral Exanthem&quot;. ( 26646426 )	Chuh A....Zawar V.	2016
50	Image Gallery: A case of unilateral laterothoracic exanthem. ( 27996140 )	Woo S.H....Park J.	2016

Sources

Genes for Exanthem

Genes related to Exanthem (0 elite genes):

(show all 20)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	EGFR	Epidermal Growth Factor Receptor	Protein Coding	17.5	DISEASES inferred ¹⁵
2	IL1RN	Interleukin 1 Receptor Antagonist	Protein Coding	17.28	DISEASES inferred ¹⁵
3	NLRP3	NLR Family Pyrin Domain Containing 3	Protein Coding	16.98	DISEASES inferred ¹⁵
4	TLR9	Toll Like Receptor 9	Protein Coding	16.59	DISEASES inferred ¹⁵ ¹⁵
5	CRP	C-Reactive Protein	Protein Coding	16.58	DISEASES inferred ¹⁵
6	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	16.54	DISEASES inferred ¹⁵
7	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	16.43	DISEASES inferred ¹⁵
8	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	16.32	DISEASES inferred ¹⁵
9	TNFRSF1B	TNF Receptor Superfamily Member 1B	Protein Coding	16.27	DISEASES inferred ¹⁵
10	HSPG2	Heparan Sulfate Proteoglycan 2	Protein Coding	16.18	DISEASES inferred ¹⁵
11	TRIM21	Tripartite Motif Containing 21	Protein Coding	16.1	DISEASES inferred ¹⁵
12	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	15.97	DISEASES inferred ¹⁵
13	TNF	Tumor Necrosis Factor	Protein Coding	15.96	DISEASES inferred ¹⁵
14	IL2	Interleukin 2	Protein Coding	15.81	DISEASES inferred ¹⁵
15	IL6	Interleukin 6	Protein Coding	15.74	DISEASES inferred ¹⁵
16	KALRN	Kalirin RhoGEF Kinase	Protein Coding	15.74	DISEASES inferred ¹⁵
17	MAP2K7	Mitogen-Activated Protein Kinase Kinase 7	Protein Coding	15.68	DISEASES inferred ¹⁵
18	CTLA4	Cytotoxic T-Lymphocyte Associated Protein 4	Protein Coding	15.67	DISEASES inferred ¹⁵
19	AREG	Amphiregulin	Protein Coding	6.82	DISEASES inferred ¹⁵ ¹⁵
20	SENP8	SUMO Peptidase Family Member, NEDD8 Specific	Protein Coding	6.56	DISEASES inferred ¹⁵

Sources

Variations for Exanthem

Sources

Expression for Exanthem

Search GEO for disease gene expression data for Exanthem.

Sources

Pathways for Exanthem

Pathways related to Exanthem according to GeneCards Suite gene sharing:

(show top 50) (show all 112)

#	Super pathways	Score	Top Affiliating Genes
1	Apoptotic Pathways in Synovial Fibroblasts ⁶⁴ Show member pathways Actin-Based Motility by Rho Family GTPases ⁶⁴ Cellular Apoptosis Pathway ⁶⁴ DHA Signaling ⁶⁴ eIF2 Pathway ⁶⁴ ERK5 Signaling ⁶⁴ Glioma Invasiveness ⁶⁴ Mitochondrial Apoptosis ⁶⁴ Nuclear Receptor Activation by Vitamin-A ⁶⁴ p53 Mediated Apoptosis ⁶⁴ PPAR Pathway ⁶⁴ Rac1 Pathway ⁶⁴ Rap1 Pathway ⁶⁴ Telomerase Components in Cell Signaling ⁶⁴	13.96	AREG EGFR ERBB2 HRAS IL2 IL6
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.96	AREG EGFR ERBB2 HRAS HSPG2 IL2
3	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.87	CRP CTLA4 EGFR ERBB2 HRAS IL1RN
4	PEDF Induced Signaling ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Cytokine-cytokine receptor interaction ³⁷ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Mediated Glucocorticoid Regulation ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.77	EGFR ERBB2 HRAS IL1RN IL2 IL6
5	Activation of cAMP-Dependent PKA ⁶⁴ Show member pathways Activation of PKA through GPCR ⁶⁴ cAMP Pathway ⁶⁴ PKA Signaling ⁶⁴	13.67	AREG CRP EGFR ERBB2 HRAS IL2
6	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.61	AREG EGFR ERBB2 HRAS IL2 IL6
7	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.43	EGFR ERBB2 HRAS IL1RN IL2 IL6
8	CREB Pathway ⁶⁴ Show member pathways Activation of PKC through GPCR ⁶⁴ Intracellular Calcium Signaling ⁶⁴ IP3 Pathway ⁶⁴	13.41	AREG EGFR ERBB2 HRAS IL2 IL6
9	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.41	AREG EGFR ERBB2 HRAS IL2 IL6
10	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.37	AREG EGFR ERBB2 HRAS IL2 IL6
11	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.36	AREG EGFR ERBB2 HRAS IL2 IL6
12	IL-2 Pathway ⁶⁴ Show member pathways ErbB Family Pathway ⁶⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-4 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ Prolactin Signaling ⁶⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.26	AREG EGFR ERBB2 HRAS IL2 KRAS
13	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.16	AREG EGFR HRAS HSPG2 IL2 IL6
14	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	13.15	AREG EGFR HRAS IL2 IL6 KRAS
15	Human cytomegalovirus infection ³⁷ Show member pathways Hepatitis B ³⁷ Human immunodeficiency virus 1 infection ³⁷ Kaposi sarcoma-associated herpesvirus infection ³⁷	13.11	EGFR HRAS HSPG2 IL6 KRAS MAP2K7
16	Toll-like Receptor Signaling Pathway ³⁷ ¹ Show member pathways Chagas disease (American trypanosomiasis) ³⁷ NOD-like receptor signaling pathway ³⁷ NOD-like Receptor Signaling Pathways ⁶⁵ Regulation of toll-like receptor signaling pathway ¹	13.1	IL2 IL6 MAP2K7 NLRP3 TLR9 TNF
17	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ DR3 Signaling ⁶⁴ Fas Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	13.05	EGFR HRAS IL6 KRAS MAP2K7 MTOR
18	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.99	AREG EGFR ERBB2 HRAS IL2 IL6
19	Allograft rejection ¹ ³⁷ Show member pathways Antigen processing and presentation ³⁷ Asthma ³⁷ Autoimmune thyroid disease ³⁷ CTL Mediated Apoptosis ⁶⁴ Graft-versus-host disease ³⁷ Intestinal immune network for IgA production ³⁷ THC Differentiation Pathway ⁶⁴ Type I diabetes mellitus ³⁷ Viral myocarditis ³⁷	12.98	CTLA4 HRAS IL2 IL6 TNF TNFRSF1B
20	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.98	AREG EGFR ERBB2 HRAS KRAS MTOR
21	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.98	EGFR ERBB2 HRAS IL6 KRAS MAP2K7
22	Pathways in cancer ³⁷	12.94	EGFR ERBB2 HRAS IL2 IL6 KRAS
23	Influenza A ³⁷ Show member pathways Herpes simplex infection ³⁷ Measles ³⁷	12.9	IL2 IL6 MAP2K7 NLRP3 TLR9 TNF
24	Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁵ Show member pathways Adipokines and Insulin Signaling Pathways ⁶⁵ Development Thrombopoietin-regulated cell processes ²² IL-15 Signaling Pathways ⁶⁵ IL-2 Signaling Pathways ⁶⁵ IL-21 Signaling Pathways ⁶⁵ IL-4 Signaling Pathways ⁶⁵ IL-7 Signaling Pathways ⁶⁵ IL-9 Pathway ⁶⁴ IL-9 Signaling Pathways ⁶⁵ Immune response IL-9 signaling pathway ²²	12.88	HRAS IL2 IL6 KRAS MTOR TNF
25	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.87	EGFR ERBB2 HRAS IL6 KRAS MAP2K7
26	MAPK signaling pathway ³⁷ ¹	12.86	AREG EGFR ERBB2 HRAS KRAS MAP2K7
27	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.85	EGFR ERBB2 HRAS KRAS MTOR
28	Downstream signaling events of B Cell Receptor (BCR) ⁶⁶ Show member pathways Activation of RAS in B cells ⁶⁶ Signaling by the B Cell Receptor (BCR) ⁶⁶	12.81	EGFR ERBB2 HRAS KRAS MTOR
29	Development HGF signaling pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development Neurotrophin family signaling ²² MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ Neurotrophin signaling pathway ³⁷ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.8	ERBB2 HRAS KRAS MAP2K7 MTOR
30	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.8	AREG EGFR IL2 IL6 TLR9 TNF
31	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.79	EGFR HRAS KRAS MAP2K7 TNF TNFRSF1B
32	Development Endothelin-1/EDNRA signaling ²² Show member pathways Cytoskeleton remodeling FAK signaling ²² Development Endothelin-1/EDNRA transactivation of EGFR ²² GnRH signaling pathway ³⁷ Inflammatory mediator regulation of TRP channels ³⁷	12.76	EGFR HRAS KRAS MAP2K7 MTOR
33	Immune response NFAT in immune response ²² Show member pathways Immune response CD28 signaling ²² Immune response ICOS pathway in T-helper cell ²² Immune response T cell receptor signaling pathway ²²	12.72	HRAS IL2 MAP2K7 TNF TNFRSF1B
34	TRAF Pathway ⁶⁴ Show member pathways 14-3-3 Induced Apoptosis ⁶⁴ TNF Superfamily Pathway ⁶⁴ Toll-Like Receptors Pathway ⁶⁴	12.7	HRAS MAP2K7 TLR9 TNF TNFRSF1B
35	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.69	EGFR ERBB2 HRAS IL2 IL6 KRAS
36	NF-kappaB Signaling ⁴	12.68	CTLA4 IL1RN IL2 TLR9 TNF TNFRSF1B
37	MicroRNAs in cancer ³⁷	12.62	EGFR ERBB2 HRAS KRAS MTOR
38	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.61	AREG EGFR ERBB2 HRAS KRAS MAP2K7
39	Prolactin Signaling Pathway ¹ ³⁷ Show member pathways Development Prolactin receptor signaling ²² Leptin signaling pathway ¹	12.59	ERBB2 HRAS IL1RN KRAS MTOR
40	Apoptosis Pathway ⁷² Show member pathways Akt Pathway ⁷² NF-kappaB Pathway ⁷²	12.54	EGFR ERBB2 HRAS IL2 KRAS MTOR
41	mTOR signaling pathway (KEGG) ⁶⁵ Show member pathways mTOR signaling pathway ³⁷	12.54	EGFR ERBB2 HRAS KRAS MTOR TNF
42	VEGF Pathway (Qiagen) ²² Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶⁴ Neurophilin interactions with VEGF and VEGFR ⁶⁶ VEGF Family Ligands and Receptor Interactions ⁶⁴ VEGF Pathway ⁶⁴	12.53	EGFR HRAS KRAS MAP2K7 TLR9
43	Human T-cell leukemia virus 1 infection ³⁷	12.53	HRAS IL2 IL6 KRAS TNF
44	JAK-STAT signaling pathway (KEGG) ³⁷ Show member pathways Interleukin-19, 20, 22, 24 ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵	12.52	EGFR HRAS IL2 IL6 KRAS MTOR
45	ErbB signaling pathway ¹ ³⁷ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶¹ Renal cell carcinoma ³⁷ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.5	AREG EGFR ERBB2 HRAS KRAS MAP2K7
46	Phospholipase D signaling pathway ³⁷ Show member pathways Choline metabolism in cancer ³⁷	12.48	EGFR HRAS KRAS MTOR
47	MET promotes cell motility ⁶⁶ Show member pathways Alpha 6 Beta 4 signaling pathway ¹ Laminin interactions ⁶⁶ MET activates PTK2 signaling ⁶⁶ MET activates RAP1 and RAC1 ⁶⁶ MET activates RAS signaling ⁶⁶ MET interacts with TNS proteins ⁶⁶ MET Receptor Activation ⁶⁶ MET receptor recycling ⁶⁶ Signaling by MET ⁶⁶	12.43	HRAS HSPG2 KRAS MTOR
48	Selenium Micronutrient Network ¹ Show member pathways Folate Metabolism ¹ Metabolism of ingested MeSeO2H into MeSeH ⁶⁶ thioredoxin pathway ¹ Vitamin B12 Metabolism ¹	12.42	CRP IL2 IL6 TNF
49	T cell receptor signaling pathway ³⁷ Show member pathways T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.41	CTLA4 HRAS IL2 IL6 KRAS MAP2K7
50	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2-ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB2 events in ERBB2 signaling ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶ PI3K events in ERBB2 signaling ⁶⁶ PI3K events in ERBB4 signaling ⁶⁶ PLCG1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB4 signaling ⁶⁶	12.4	EGFR ERBB2 HRAS KRAS

Sources

GO Terms for Exanthem

Cellular components related to Exanthem according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.76	AREG CRP EGFR HSPG2 IL1RN IL2
2	extracellular region	GO:0005576	9.32	CRP EGFR HSPG2 IL1RN IL2 IL6
3	membrane raft	GO:0045121	9.26	EGFR KRAS TNF TNFRSF1B

Biological processes related to Exanthem according to GeneCards Suite gene sharing:

(show all 44)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.99	EGFR ERBB2 HRAS TNF
2	cellular response to lipopolysaccharide	GO:0071222	9.93	IL1RN IL6 NLRP3 TNF TNFRSF1B
3	cytokine-mediated signaling pathway	GO:0019221	9.93	IL1RN IL2 IL6 KRAS TNF TNFRSF1B
4	positive regulation of protein kinase B signaling	GO:0051897	9.92	EGFR ERBB2 MTOR TNF
5	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.89	IL6 KRAS NLRP3 TLR9 TNF
6	defense response to Gram-positive bacterium	GO:0050830	9.88	CRP IL6 NLRP3 TNF
7	positive regulation of JNK cascade	GO:0

Exanthem (RASH)

Aliases & Classifications for Exanthem

MalaCards integrated aliases for Exanthem:

Classifications:

External Ids:

Summaries for Exanthem

Related Diseases for Exanthem

Diseases in the Exanthem family:

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Exanthem:

Symptoms & Phenotypes for Exanthem

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Exanthem:

Drugs & Therapeutics for Exanthem

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Cochrane evidence based reviews: exanthema

Genetic Tests for Exanthem

Anatomical Context for Exanthem

MalaCards organs/tissues related to Exanthem:

Publications for Exanthem

Articles related to Exanthem:

Genes for Exanthem

Genes related to Exanthem (0 elite genes):

Variations for Exanthem

Expression for Exanthem

Pathways for Exanthem

Pathways related to Exanthem according to GeneCards Suite gene sharing:

GO Terms for Exanthem

Cellular components related to Exanthem according to GeneCards Suite gene sharing:

Biological processes related to Exanthem according to GeneCards Suite gene sharing: